221 related articles for article (PubMed ID: 33022750)
1. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.
Zhou P; Goffredo P; Ginader T; Thompson D; Hrabe J; Gribovskaja-Rupp I; Kapadia M; Hassan I
J Surg Oncol; 2021 Jan; 123(1):278-285. PubMed ID: 33022750
[TBL] [Abstract][Full Text] [Related]
2. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.
Shahab D; Gabriel E; Attwood K; Ma WW; Francescutti V; Nurkin S; Boland PM
Clin Colorectal Cancer; 2017 Dec; 16(4):300-307. PubMed ID: 28420585
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N
Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609
[TBL] [Abstract][Full Text] [Related]
5. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer.
Karagkounis G; Thai L; Mace AG; Wiland H; Pai RK; Steele SR; Church JM; Kalady MF
Ann Surg; 2019 Jun; 269(6):1117-1123. PubMed ID: 31082910
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Neoadjuvant Rectal Score and Indication for Postoperative Adjuvant Therapy in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy.
Maeda K; Shibutani M; Tachimori A; Nishii T; Aomatsu N; Fukuoka T; Nagahara H; Otani H; Inoue T; Ohira M
In Vivo; 2020; 34(1):283-289. PubMed ID: 31882490
[TBL] [Abstract][Full Text] [Related]
8. Validation of the Neoadjuvant Rectal Cancer (NAR) Score for Prognostication Following Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer.
Shah S; Asawa P; Abel S; Wegner RE
J Gastrointest Cancer; 2023 Sep; 54(3):829-836. PubMed ID: 36253514
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
[TBL] [Abstract][Full Text] [Related]
10. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
[TBL] [Abstract][Full Text] [Related]
11. Ten-year survival after pathologic complete response in rectal adenocarcinoma.
Sell NM; Qwaider YZ; Goldstone RN; Cauley CE; Cusack JC; Ricciardi R; Bordeianou LG; Berger DL; Kunitake H
J Surg Oncol; 2021 Jan; 123(1):293-298. PubMed ID: 33022797
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response.
Turner MC; Keenan JE; Rushing CN; Gulack BC; Nussbaum DP; Benrashid E; Hyslop T; Strickler JH; Mantyh CR; Migaly J
J Gastrointest Surg; 2019 Aug; 23(8):1614-1622. PubMed ID: 30635829
[TBL] [Abstract][Full Text] [Related]
13. The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiation.
Tawfik B; Mokdad AA; Patel PM; Li HC; Huerta S
Anticancer Drugs; 2016 Oct; 27(9):879-83. PubMed ID: 27434664
[TBL] [Abstract][Full Text] [Related]
14. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study.
Shaish H; Aukerman A; Vanguri R; Spinelli A; Armenta P; Jambawalikar S; Makkar J; Bentley-Hibbert S; Del Portillo A; Kiran R; Monti L; Bonifacio C; Kirienko M; Gardner KL; Schwartz L; Keller D
Eur Radiol; 2020 Nov; 30(11):6263-6273. PubMed ID: 32500192
[TBL] [Abstract][Full Text] [Related]
15. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
[TBL] [Abstract][Full Text] [Related]
16. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
Hu-Lieskovan S; Vallbohmer D; Zhang W; Yang D; Pohl A; Labonte MJ; Grimminger PP; Hölscher AH; Semrau R; Arnold D; Dellas K; Debucquoy A; Haustermans K; Machiels JP; Sempoux C; Rödel C; Bracko M; Velenik V; Lenz HJ
Clin Cancer Res; 2011 Aug; 17(15):5161-9. PubMed ID: 21673069
[TBL] [Abstract][Full Text] [Related]
17. Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
Greenbaum A; Martin DR; Bocklage T; Lee JH; Ness SA; Rajput A
Clin Colorectal Cancer; 2019 Jun; 18(2):102-109. PubMed ID: 30935775
[TBL] [Abstract][Full Text] [Related]
18. Evaluating disparities in delivery of neoadjuvant guideline-based chemoradiation for rectal cancer: A multicenter, propensity score-weighted cohort study.
Lau LW; Kethman WC; Bingmer KE; Ofshteyn A; Steinhagen E; Charles R; Dietz D; Stein SL
J Surg Oncol; 2021 Oct; 124(5):810-817. PubMed ID: 34159619
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of neoadjuvant rectal score in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and construction of a prediction model.
Sun Y; Zhang Y; Wu X; Lin H; Lu X; Huang Y; Xu Z; Huang S; Wang X; Chi P
J Surg Oncol; 2018 Mar; 117(4):737-744. PubMed ID: 29228455
[TBL] [Abstract][Full Text] [Related]
20. The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long-term outcome in locally advanced rectal cancer.
McMahon RK; O'Cathail SM; Nair H; Steele CW; Platt JJ; Digby M; McDonald AC; Horgan PG; Roxburgh CSD
Colorectal Dis; 2023 Sep; 25(9):1783-1794. PubMed ID: 37485654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
